

Form PTO-1594 (Rev. 07/05)  
OMB Collection 0651-0027 (exp. 6/30/2008)

U.S. DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office

### RECORDATION FORM COVER SHEET TRADEMARKS ONLY

To the Director of the U. S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

**1. Name of conveying party(ies):**

Shire Laboratories, Inc.

- Individual(s)
- General Partnership
- Corporation- State: Delaware
- Other \_\_\_\_\_
- Association
- Limited Partnership

Citizenship (see guidelines) \_\_\_\_\_

Additional names of conveying parties attached?  Yes  No

**3. Nature of conveyance /Execution Date(s) :**

Execution Date(s) 12/22/2005

- Assignment
- Security Agreement
- Other \_\_\_\_\_
- Merger
- Change of Name

**2. Name and address of receiving party(ies)**

Additional names, addresses, or citizenship attached?  Yes  No

Name: Supernus Pharmaceuticals, Inc.

Internal Address: \_\_\_\_\_

Address: \_\_\_\_\_

Street Address: 1550 East Gude Drive

City: Rockville

State: MD

Country: USA Zip: 20850

- Association
- General Partnership
- Limited Partnership
- Corporation
- Other \_\_\_\_\_

Citizenship \_\_\_\_\_  
If assignee is not domiciled in the United States, a domestic representative designation is attached:  Yes  No  
(Designations must be a separate document from assignment)

**4. Application number(s) or registration number(s) and Identification or description of the Trademark.**

A. Trademark Application No.(s) 78488655; 78277674; 78485585; 78558827; 78558949; 78558951

B. Trademark Registration No.(s) 2290327; 2108880; 2764810; 2410482; 2505388; 2012375; 2770361; 2846419

Additional sheet(s) attached?  Yes  No

**C. Identification or Description of Trademark(s) (and Filing Date if Application or Registration Number is unknown):**

**5. Name & address of party to whom correspondence concerning document should be mailed:**

Name: Helen Hill Minsker

Internal Address: \_\_\_\_\_

Banner & Witcoff, Ltd.

Street Address: 1001 G Street, NW

City: Washington

State: D.C. Zip: 20001

Phone Number: 202-824-3000

Fax Number: 202-824-3001

Email Address: hminsker@bannerwitcoff.com

**6. Total number of applications and registrations involved:**

**14**

**7. Total fee (37 CFR 2.6(b)(6) & 3.41) \$ 365.00**

- Authorized to be charged by credit card
- Authorized to be charged to deposit account
- Enclosed

**8. Payment Information:**

a. Credit Card Last 4 Numbers \_\_\_\_\_  
Expiration Date \_\_\_\_\_

b. Deposit Account Number 19-0733

Authorized User Name Helen Hill Minsker

**9. Signature:**

3/30/06  
Date

Helen Hill Minsker

Name of Person Signing

Total number of pages including cover sheet, attachments, and document: **7**

Documents to be recorded (including cover sheet) should be faxed to (571) 273-0140, or mailed to:  
Mail Stop Assignment Recordation Services, Director of the USPTO, P.O. Box 1450, Alexandria, VA 22313-1450

CH \$365.00 190733 78488655

## AGREEMENT

This ASSIGNMENT is by and between Supernus Pharmaceuticals, Inc., a Delaware corporation ("Supernus"), and Shire Laboratories Inc., a Delaware corporation ("SLI").

WHEREAS, SLI has applied to register with the U.S. Patent and Trademark Office ("PTO") the marks in Table 1, below, based on its bona fide intention to use the marks in commerce in connection with the goods and services indicated in Table 1;

Table 1

MARK	COUNTRY	APPL. NO.	GOODS/ SERVICES
AVERT	USA	78/488,655	chemical additives for use in the manufacture of pharmaceuticals, namely, formulations containing agents to deter abuse of a particular drug
AVERTABUSE	USA	78/488,674	chemical additives for use in the manufacture of pharmaceuticals, namely, formulations containing agents to deter abuse of a particular drug
MAPS (Multipulse Absorption Prediction System)	USA	78/169,226	Computer services, namely modelling, analysis and predictive simulations of pharmaceuticals
MICROMATRIX CORES	USA	78/105,210	Chemical additives for use in the manufacture of pharmaceuticals, namely, formulations which promote extended release for pharmaceutical agents for oral or buccal delivery
PEAK	USA	78/203,047	Drug discovery and development services utilizing predictive simulations of pharmaceutical profiles, namely, discovery and development of drug formulations to facilitate the introduction of drugs into the body via transdermal, oral or intravenous means
PROPHILE	USA	78/277,674	Pharmaceutical drug development services
RADAR	USA	78/485,585	Laboratory research services for others, namely, evaluating the permeability and absorption of oral pharmaceuticals in animals and humans
RADAR	USA	78/170,740	laboratory services for others, namely evaluating the permeability of oral pharmaceuticals in human intestinal tissue
RAPITROL	USA	78/100,407	Chemical additives for use in the manufacture of pharmaceuticals, namely, formulations which promote immediate release for pharmaceutical

			agents for oral or buccal delivery
SUPERNUS	USA	78/558,827	<p>IC 001. US 001 005 006 010 026 046. G &amp; S: Chemicals and excipients used in the manufacture of pharmaceuticals, namely, formulations which promote controlled release, reduced abuse potential, enhanced solubility, enhanced permeability or enhanced absorption of pharmaceutical agents</p> <p>IC 005. US 006 018 044 046 051 052. G &amp; S: Pharmaceuticals preparations for the treatment of central nervous system disorders, cardiovascular disorders, urologic disorders, infectious and viral disorders, respiratory disorders, gastrointestinal disorders, metabolic diseases, and pain; Full line of pharmaceutical and medical preparations and substances</p> <p>IC 042. US 100 101. G &amp; S: Pharmaceutical drug development and screening services; Development services for others, namely, evaluating the permeability and absorption of pharmaceuticals in the body and developing formulations to facilitate and improve the delivery of drugs into the body; pharmaceutical screening services, namely, cell-based in vitro and in vivo screening services</p>
SUPERNUS PHARMACEUTICALS	USA	78/558,949	<p>IC 001. US 001 005 006 010 026 046. G &amp; S: Chemicals and excipients used in the manufacture of pharmaceuticals, namely, formulations which promote controlled release, reduced abuse potential, enhanced solubility, enhanced permeability or enhanced absorption of pharmaceutical agents</p> <p>IC 005. US 006 018 044 046 051 052. G &amp; S: Pharmaceuticals preparations for the treatment of central nervous system disorders, cardiovascular disorders, urologic disorders, infectious and viral disorders, respiratory disorders, gastrointestinal disorders, metabolic diseases, and pain; Full line of pharmaceutical and medical preparations and substances</p> <p>IC 042. US 100 101. G &amp; S: Pharmaceutical drug development and screening services; Development services for others, namely, evaluating the permeability and absorption of pharmaceuticals in the body and developing formulations to facilitate and improve the delivery of drugs into the body; pharmaceutical screening services, namely, cell-based in vitro and in vivo</p>

			screening services
SUPERNUS PHARMACEUTICALS & Design	USA	78/558,951	<p>IC 001. US 001 005 006 010 026 046. G &amp; S: Chemicals and excipients used in the manufacture of pharmaceuticals, namely, formulations which promote controlled release, reduced abuse potential, enhanced solubility, enhanced permeability or enhanced absorption of pharmaceutical agents</p> <p>IC 005. US 006 018 044 046 051 052. G &amp; S: Pharmaceutical preparations for the treatment of central nervous system disorders, cardiovascular disorders, urologic disorders, infectious and viral disorders, respiratory disorders, gastrointestinal disorders, metabolic diseases, and pain; Full line of pharmaceutical and medical preparations and substances</p> <p>IC 042. US 100 101. G &amp; S: Pharmaceutical drug development and screening services; Development services for others, namely, evaluating the permeability and absorption of pharmaceuticals in the body and developing formulations to facilitate and improve the delivery of drugs into the body; pharmaceutical screening services, namely, cell-based in vitro and in vivo screening services</p>

WHEREAS, SLI is the owner of all right, title and interest in and to the registered trademarks listed in Table 2, below, for use on and in connection with the goods and services indicated in Table 2;

Table 2

TM NAME	COUNTRY	APPL. NO	REG. NO	GOODS/SERVICES
DERMATROL	USA	74/545,262	2290327	transdermal patches for use in the treatment of disorders of the central nervous system, emesis, cancer, endocrine disorders, metabolic disorders, and cardiovascular disorders.
ENSOTROL (Stylized)	USA	75/174,439	2,108,880	chemical additives for use in the manufacture of pharmaceuticals, namely, formulations which permit enhanced solubility and controlled oral delivery of pharmaceutical agents

LIQUIBEAD	USA	76/138,865	2,764,810	CHEMICAL ADDITIVES FOR USE IN THE MANUFACTURE OF PHARMACEUTICALS, NAMELY, ADDITIVES WHICH PERMIT ORAL DELIVERY FOR INCREASED DRUG LOADING, ENHANCED SOLUBILITY OR ENHANCED ABSORPTION OF PHARMACEUTICAL PRODUCTS
MICROTROL	USA	75/832,194	2,410,482	chemical additives for use in the manufacture of pharmaceuticals, namely, formulations which permit oral sustained release and enhanced solubility of pharmaceutical products
OPTISCREEN	USA	75/861,068	2,505,388	SCREENING SERVICES, NAMELY, CELL-BASED, IN VITRO, AND IN VIVO SCREENING SERVICES
PEPTISCREEN	USA	74/545,261	2,012,375	pharmaceutical screening services, namely a cell culture-based screening service which shows the degree of transport of drug molecules across physiological membranes
PEPTITROL	USA	74/545,260	2,246,284	formulations of hydrophobic, hydrophilic or surface-active ingredients, or combinations thereof, used in drug delivery systems which permit the oral delivery of difficult to deliver pharmaceuticals including peptides, sold only as a component of pharmaceuticals with poor oral bioavailability
PROSCREEN	USA	78/116,161	2,770,361	Laboratory testing services for others, namely testing excipients or ingredients used in formulations which promote extended release or enhanced bioavailability for pharmaceutical agents for drug delivery and determining the suitability of different drug delivery technologies to achieve a specific pharmaceutical dosage form
SOLUTROL	USA	78/100,409	2,846,419	Chemical additives for use in the manufacture of pharmaceuticals, namely, formulations which promote extended modified release for highly water soluble pharmaceutical agents

(the applications and registrations of Tables 1 and 2, collectively, the "Marks")

WHEREAS, through the "Asset Purchase and Contribution Agreement" dated December 22, 2005, SLI agreed to assign to Supernus all right, title and interest in and to the Marks, including the goodwill of the business connected therewith, and also agreed to

transfer to Supernus the portion of the business of SLI in connection with which SLI has a bona fide intention to use the Marks;

NOW, THEREFORE, SLI, in consideration of the sum of Ten Dollars (\$10.00), or the equivalent thereof, and other good and valuable consideration, the sufficiency of which and receipt of which are hereby acknowledged, paid to it by Supernus, does hereby sell and assign to Supernus, its successors and assigns, all of its right, title and interest in and to the Marks together with the goodwill of the business connected therewith, and together with the portion of the business in connection with which SLI has a bona fide intention to use the Marks.

SLI hereby authorizes and requests the Commissioner of Patents and Trademarks and any other granting authority to issue any Registrations resulting from the Marks concerning same to Supernus;


This assignment shall have an effective date of December 22, 2005.

I declare under penalty of perjury under the laws of the United States of America, and under penalty of the laws of any other jurisdiction before which this document may be presented, that I am an officer of the above-identified SLI, that I have signed this document on behalf of SLI with the full authority of its board of directors, and that all of the foregoing is true and correct.

SHIRE LABORATORIES, INC.


Dated: \_\_\_\_\_

By: \_\_\_\_\_



Name: \_\_\_\_\_

Title: \_\_\_\_\_



**ACCEPTANCE BY ASSIGNEE**

I hereby accept this assignment on behalf of said Supernus. I declare under penalty of perjury under the laws of the United States of America, and under penalty of the laws of any other jurisdiction before which this document may be presented, that I am an officer of the above-identified Supernus, that I have signed this document on behalf of Supernus with the full authority of its board of directors, and that all of the foregoing is true and correct.

SUPERNUS PHARMACEUTICALS, INC.

Dated: March 15, 2006

By:



Name:

Jack Khattar

Title:

President + CEO

\*